Sitagliptin, the first oral DPP-4 inhibitor to be marketed for treating Type 2 Diabetes
Learn more detailes about PEG linkers and its applications in pharmaceutical field.
In view of the complexity of cancer treatment and peoples needs, the market prospects of anti-tumor drugs are broad. Many pharmaceutical and biotechnology companies have stepped up research a…
Antibody-drug conjugates (ADCs) are a rapidly evolving class of anticancer therapeutics consisting of antibodies attached to potent cytotoxic drugs via chemical linkers.
There are three CDK4/6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib approved by FDA to treat Advanced Breast Cancer.